Irritable Bowel Syndrome Clinical Trial
Official title:
Multicenter Trial of Functional Bowel Disorders
The primary purpose for this study is to compare clinical treatments for patients with
functional bowel disorders (irritable bowel syndrome, abdominal pain, painful constipation)
in women. We also plan to: 1) determine what clinical features (medical or psychological)
determine which patients will improve to these treatments, and 2) understand if there are
any physiological features that relate to improvement in symptoms and response to the
treatments.
We will compare a psychological treatment (cognitive-behavioral therapy - CBT) with
education/attention placebo, and an antidepressant drug (desipramine) with a pill placebo.
This is the first large-scale study designed to determine the therapeutic effects of these
methods, and to also determine interactions among physiologic measures, psychologic and
sociodemographic factors, severity of symptoms, and therapeutic improvement including
quality of life.
Status | Completed |
Enrollment | 300 |
Est. completion date | March 2001 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Literate, female patients aged 18-65. - Symptoms present at least 2 days/week for greater than 6 months. - Diagnosis of functional bowel disorder (to be subcategorized using ''Rome'' Criteria. - Moderate (MFBD) or severe (SFBD) functional bowel disorder (FBD) based on the Functional Bowel Disorder Severity Index (FBDSI) developed in our pilot study. SFBD will be defined as a score of 110 and MFBD will be defined as a score between 36 and 110. - Discontinuation of all antidepressant medications for at least 3 months. - Use of acceptable method of birth control. Exclusion Criteria: - Evidence of lactose intolerance to explain bowel symptoms. - Heart disease. - Cardiac arrhythmias. - Severe psychiatric disorder (e.g., bipolar, suicide attempts). - Previous use of desipramine. - Glaucoma. - Urinary retention. - Pregnancy. - Alcohol consumption 3oz/day that would preclude participation or prevent data assessment. - Systemic gastrointestinal diseases or previous surgery that would interfere with the interpretation of symptoms or physiology. - Bipolar disorder. - Schizophrenia. - Substance abuse/dependency. - Previous use of desipramine. |
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Centre for Addiction and Mental Health, Clark Site | Toronto | Ontario |
United States | UNC Center for Functional GI Motility Disorders | Chapel Hill | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States, Canada,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |